This is a randomised controlled trial to determine the effectiveness of Vericiguat to improve stress myocardial blood flow (MBF) and myocardial perfusion reserve as measured by cardiac magnetic resonance (CMR) imaging.
Stable recurrent chest pain.
40 to 75 years old.
Have coronary computed tomography (CT) angiogram or catheter coronary angiogram within 6 months showing non-obstructive coronary artery disease (<50% coronary artery stenosis or fractional flow reserve >0.8).
Stress CMR MPR <2.19 12 or Stress MBF <2.19ml/g/min 13.
Systolic blood pressure <100 mm Hg.
Concurrent use of soluble guanylate cyclase stimulators (eg. Riociguat), or phosphodiesterase type 5 inhibitors (eg. vardenafil, tadalafil, and sildenafil).
Has known allergy or sensitivity to any soluble guanylate cyclase stimulator.
On long-acting nitrates (eg. isosorbide mononitrate)